VFC Resolution: Vaccines to Prevent COVID-19

Jeanne M. Santoli (jsantoli@cdc.gov)
Immunization Services Division
National Center for Immunization and Respiratory Diseases
October 2022
Overview

Purpose of the Resolution

- The purpose of this resolution is to add vaccines for the prevention of COVID-19 to the VFC program.
Eligible Groups

- All children aged 6 months through 18 years
COVID-19 vaccines that are either authorized under Emergency Use Authorization (EUA) or approved under a Biologics License Application (BLA) are to be administered according to the most recent age- and vaccine-appropriate schedule included in CDC’s Interim Clinical Considerations for COVID-19 vaccines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html).
Recommended Dosage/Contraindications

Recommended dosage
- Dosage information is available online at: COVID-19 Vaccines | FDA.

Contraindications and Precautions
- Contraindications and precautions are available in CDC’s Interim Clinical Considerations for COVID-19 vaccines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html).
Vaccine Availability through VFC

- COVID-19 vaccines will not be available through the VFC program immediately following the passage of this resolution because they remain available for all Americans under the USG’s National COVID-19 Response.

- Following the passage of this resolution, CDC will begin the steps necessary to award contracts for COVID-19 vaccines.

- Once COVID-19 vaccines are commercialized and no longer available under the USG’s National COVID-19 Response, VFC providers will be able to order the vaccines through the VFC program.

- The timeline for commercialization of COVID-19 vaccines in the US has not yet been finalized.